

Sistema UroLift® - Bibliografia Seleccionada

Guidelines

1. Parsons JK, Dahm P, Köhler TS et al: Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA Guideline amendment 2020. *J Urol* 2020; 204: 799.
 - a. Link para guidelines: [https://www.auanet.org/guidelines/guidelines/benign-prostatic-hyperplasia-\(bph\)-guideline](https://www.auanet.org/guidelines/guidelines/benign-prostatic-hyperplasia-(bph)-guideline)
 - b. Link para a atualização de 2020: <https://www.auanet.org/documents/Guidelines/PDF/BPH-Amendment-2020.pdf>
2. European Association of Urology (EAU) guidelines on management of non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO).
 - a. Link para guidelines: <https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/>
3. Surgical and interventional management of benign prostatic obstruction: Guidelines from the Committee for Male Voiding Disorders of the French Urology Association. *Prog Urol* 2021; 31(5): 249-265.
 - a. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/33478868/>
4. NICE Medical Technologies Guidance (MTG58). UroLift for treating lower urinary tract symptoms of benign prostatic hyperplasia. 2021.
 - a. Link para o guia: <https://www.nice.org.uk/guidance/MTG58>
5. NICE Interventional Procedure Guidance (IPG475). Insertion of prostatic urethral lift implants to treat lower urinary tract symptoms secondary to benign prostatic hyperplasia. 2014.
 - a. Link para o guia: <https://www.nice.org.uk/guidance/ipg475>

Meta-Análises

1. Tanneru K, Gautam S, Norez D, et al. Meta-analysis and systematic review of intermediate-term follow-up of prostatic urethral lift for benign prostatic hyperplasia. *Int Urol Nephrol*. 2020; 52(6): 999-1008.
 - a. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/32065331/>
2. Jing J, Wu Y, Du M, et al. Urethral Lift as a Safe and Effective Procedure for Prostatic Hyplasia Population: A Systematic Review and Meta-Analysis. *Front Surg*. 2020; 8(7): 598728.
 - a. Link para o artigo: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793831/pdf/fsurg-07-598728.pdf>
3. Perera M, Roberts MJ, Suhail ARD, Bolton D. Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis. *Eur Urol*. 2015; 67; 704-713. Addendum *Eur Urol* 2015; 68; E53-E54.
 - a. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/25466940/>

Estudos randomizados controlados

1. L.I.F.T. Study
 - a. Roehrborn CG, Barkin J, Gange SN, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. *Can J Urol*. 2017; 24(3): 8802-8813.
 - i. Link para o artigo: https://www.canjurol.com/html/freearticles/V24I3_08_FREE_DrRoehrborn.pdf
 - b. Roehrborn CG. Prostatic Urethral Lift A Unique Minimally Invasive Surgical Treatment of Male Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. *Urol Clin N Am*. 2016. 43:357-369.
 - i. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/27476128/>
 - c. Roehrborn CG, Rukstalis DB, Barkin J, et al. Three year results of the prostatic urethral L.I.F.T. study. *Can J Urol*. 2015; 22(3): 7772-82.
 - i. Link para o artigo: https://www.canjurol.com/html/free-articles/V22I3_05_FREE_DrRoehrborn.pdf

- d. Roehrborn CG, Gange SN, Shore ND, et al. Durability of the Prostatic Urethral Lift: 2-Year Results of the L.I.F.T. Study. *Urology Practice*. 2015; 2(1):26-32.
 - i. Link para o artigo: <https://cdn2.hubspot.net/hubfs/2618738/docs/articles/01-Roehrborn-2015-Urology-Practice.pdf?t=1531248612766>
- di. McVary KT, Gange SN, Shore ND. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. *J Sex Med*. 2014; 11(1):279-87.
 - i. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/24119101/>
- dii. Roehrborn CG, Gange SN, Shore ND, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. *J Urol*. 2013; 190(6):2161-7.
 - i. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/23764081/>
2. Estudo BPH6
 - diii. Gratzke C, Barber N, Speakman MJ. Prostatic urethral lift vs transurethral resection of the prostate: 2-year results of the BPH6 prospective, multicentre, randomized study. *BJU Int*. 2017; 119(5):767-775.
 - i. Link para o artigo: <https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1111/bju.13714>
 - div. Sonksen J, Barber NJ, Speakman MJ, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. *Eur Urol*. 2015; 68(4):643-52.
 - i. Link para o artigo (selecione "download do artigo"):
<https://www.sciencedirect.com/science/article/pii/S0302283815003267>

Estudos não-randomizados comparativos

1. Roehrborn CG, Rukstalis DB. Prostatic Urethral Lift Versus Medical Therapy: Examining the Impact on Sexual Function in Men with Benign Prostatic Hyperplasia. *Eur Urol Focus*. 2021; S2405-4569(20) 30315-1.
 - a. Link para o artigo: <https://www.eu-focus.europeanurology.com/action/showPdf?pii=S2405-4569%2820%2930315-1>
2. Tutrone RF, Schiff W. Early patient experience following treatment with the UroLift prostatic urethral lift and Rezum steam injection. *Can J Urol*. 2020; 27(3): 10213-10219.
 - a. Link para o artigo: https://www.canjurol.com/html/free-articles/Cdn_JU27-I3_06.FREE_DrTutrone.pdf

Estudos de segmento único

1. Estudo MedLift
 - a. Rukstalis D, Grier D, Stroup SP, et al. Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study. *Prostate Cancer Prostatic Dis*. 2019; 22(3): 411-419.
 - i. Link para o artigo:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6760566/pdf/41391_2018_Article_118.pdf
2. Estudo Crossover
 - a. Rukstalis D, Rashid P, Bogache W, et al. 24-month durability after crossover to the prostatic urethral lift from randomised, blinded sham. *BJU Int*. 2016; 118(Suppl 3): 14-22.
 - i. Link para o artigo: <https://bjui-journals.onlinelibrary.wiley.com/doi/epdf/10.1111/bju.13666>
 - b. Cantwell AL, Bogache WK, Richardson SF, et al. Multicentre prospective crossover study of the 'prostatic urethral lift' for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *BJU Int*. 2014; 113(4):615-22.
 - i. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/24765680/>

3. Estudo LOCAL
 - a. Shore N, Freedman S, Gange S, et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. *Can J Urol*. 2014; 21(1): 7094-101.*
 - i. Link para o artigo: https://www.canjurol.com/html/freearticles/2014/V21i1_03_FREE_DrShore.pdf
4. Primeiro estudo em humanos
 - a. Chin PT, Bolton DM, Jack G, et al. Prostatic urethral lift: Two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urology*. 2012; 79(1): 5-11.*
 - i. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/22202539/>
 - b. Woo HH, Bolton DM, Laborde E. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Sex Med*. 2012; 9(2):568-75.
 - i. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/22172161/>
 - c. Woo HH, Chin PT, McNicholas TA. Safety and feasibility of the prostatic urethral lift: a novel, minimally invasive treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). *BJU Int*. 2011; 108(1): 82-8.
 - i. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/21554526/>
5. Estudo inicial da Turquia
 - a. Bozkurt A, Karabakan M, Keskin E, Hirik E, Can Balci MB, Nuhoglu B. Prostatic Urethral Lift: A New Minimally Invasive Treatment for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. *Urol Int*. 2016; 96(2): 202-206.
 - i. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/26613256/>
 - b. Akin Y, Bozkurt A, Keles MO, Gulmez H, Sahin M, Nuhoglu B. A Novel Minimally Invasive Treatment Option for Benign Prostat Hyperplasia: Intraprostatic UroLift®, The First Case Series of Turkey with Short Term Follow-up. *JAREM*. 2013; 3: 74-8.
 - i. Link para o artigo: <https://www.readcube.com/articles/10.5152%2Fjarem.2013.19>
6. Estudo inicial da França
 - a. Beurrier S, Peyromaure M, Belas O, Delongchamps NB. Are the UroLift® implants an alternative for the treatment of benign prostatic hyperplasia? Short-term results and predictive factors of failure. *Prog Urol*. 2015; 25: 523-529.
 - i. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/25934591/>
 - b. Delongchamps NB, Conquy S, Zerbib M, Peyromaure M. Intra-prostatic UroLift(®) implants for benign prostatic hyperplasia: preliminary results of the four first cases performed in France. *Prog Urol*. 2012; 22(10): 590-7.
 - i. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/22920338/>
7. Estudo inicial da Espanha
 - a. Garrido Abad P, Coloma Del Peso A, Sinues Ojas B, Fernandez Arjona M. Urolift®, a new minimally invasive treatment for patients with low urinary tract symptoms secondary to BPH. Preliminary results. *Arch Esp Urol*. 2013; 66(96): 584-91.
 - i. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/23985459/>
8. Estudos retrospectivos de vida real (ampla população)
 - a. Rabinowitz MJ, Alam R, Liu JL, et al. Prostatic Urethral Lift in Patients With Obstructive Median Lobes: A Single Surgeon Experience at an Academic Center. *Urology*. 2021; S0090-4295(21): 00088.
 - i. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/33493510/>

- b. Eure G, Gange S, Walter P, et al. Real-World Evidence of Prostatic Urethral Lift Confirms Pivotal Clinical Study Results: 2-Year Outcomes of a Retrospective Multicenter Study. *J Endourol.* 2019; 33(7): 576-584.
 - i. Link para o artigo: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657298/pdf/end.2019.0167.pdf>
- c. Sievert KD, Schonthal M, Berges R, et al. Minimally invasive prostatic urethral lift (PUL) efficacious in TURP candidates: a multicenter German evaluation after 2 years. *World J Urol.* 2019; 37(7):1353-1360.
 - i. Link para o artigo: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620255/pdf/345_2018_Article_2494.pdf
9. Chialastri P, Chialastri A, Mueller T. Does Prostatic Urethral Lift Reduce Urinary Medications? Trends in Medical Treatment Before and After Prostatic Urethral Lift. *J Endourol.* 2021; Jan 20.
 - a. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/33198488/>
10. Kim JH, Lee KS, Kim TH et al. Evaluation of Clinical Outcomes of Prostatic Urethral Lift for Benign Prostatic Hyperplasia: An Asian Population Study. *World J Mens Health.* 2020; 38(3):338-344.
 - a. Link para o artigo: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308227/pdf/wjmh-38-338.pdf>
11. Userovici M, Ochoa A, Anract J, Beurrier S, Peyromaure M, Delongchamps NB. Prostatic urethral lift using Urolift® system for benign prostatic hyperplasia: 7 years experience. *Prog Urol.* 2020; 30(3): 147-154.
 - a. Link para o artigo (then click on View Open Manuscript): <https://www.sciencedirect.com/science/article/pii/S1166708720300221>
12. Al-Singary W, Patel R, Obi-Njoku O, Patel HRH. The UroLift® System for lower urinary tract obstruction: patient selection for optimum clinical outcome. *Minim Invasive Ther Allied Technol.* 2020; 11: 1-6.
 - a. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/32915085/>
13. Cayuelas Rubio C, Pallas Costa Y, Juan Escudero J, et al. Minimally invasive treatment for lower urinary tract symptoms due to benign prostatic hyperplasia. Our initial experience with Urolift® under local anaesthesia and sedation. *Actas Urol Esp.* 2019; 43(9): 488-494.
 - a. Link para o artigo: <https://pubmed.ncbi.nlm.nih.gov/31160158/>
14. Shah BB, Tayon K, Madiraju S, Carrion RE, Perito P. Prostatic Urethral Lift: Does Size Matter? *J Endourol.* 2018; 32(7): 635-638.
 - a. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/29631445/>
15. Bardoli AD, Taylor WSJ, Mahmalji W. Can the UroLift prostatic implant device treat the symptoms of benign prostatic hypertrophy, avoid sexual dysfunction and reduce hospital TURP waiting times? A single centre, single surgeon experience and review of the literature. *Aging Male.* 2017; 20(3):192-197.
 - a. Link para o artigo: <https://www.tandfonline.com/doi/pdf/10.1080/13685538.2017.1336531?needAccess=true>

Artigos técnicos

1. Walsh LP. State of the art: Advanced techniques for prostatic urethral lift for the relief of prostate obstruction under local anesthesia. *Can J Urol.* 2017; 24(3):8859-8864.
 - a. Link para o artigo: https://www.canjurol.com/html/free-articles/V24I3_17_FREE_DrWalsh.pdf
2. McNicholas TA, Woo HH, Chin PT. Minimally invasive prostatic urethral lift: surgical technique and multinational experience. *Eur Urol.* 2013; 64(2): 292-9.
 - a. Link para o resumo: <https://pubmed.ncbi.nlm.nih.gov/23357348/>
3. Barkin J, Giddens J, Incze P. UroLift system for relief of prostate obstruction under local anesthesia. *Can J Urol.* 2012; 19(2):6217-22.
 - a. Link para o artigo: https://www.canjurol.com/html/free-articles/V19I2-17_DrBarkin.pdf

Artigos de economia da saúde

1. Clarke JL. Optimizing Population Health and Economic Outcomes: Innovative Treatment for BPH. *Popul Health Manag.* 2013; 16(Suppl 2): S1-S13
 - a. Link para o artigo: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3883086/pdf/pop.2013.1691.pdf>

*O estudo de denota incluiu volumes da próstata maiores do que as indicações aprovadas pela FDA. O sistema UroLift não deve ser usado se o paciente tiver um volume da próstata > 100 cc. NeoTract | Teleflex não recomenda ou endossa o uso do Sistema UroLift com volumes da próstata > 100 cc.

Indicado para o tratamento de sintomas de próstata aumentada até 100 ml em homens de 50 anos de idade ou mais. Os resultados podem variar individualmente, como em qualquer procedimento médico. A maioria dos efeitos colaterais é temporária e inclui disúria, hematuria, dor pélvica, urgência urinária e incontinência de emergência (Roehrborn, J Urology 2013). Efeitos colaterais raros, entre eles sangramento e infecção, podem levar a consequências graves e exigir intervenção. Para obter mais informações, consultar as indicações aprovadas para a sua região e a bula. ifu.teleflex.com

É possível que nem todos os produtos estejam disponíveis em todos os países. Para obter informações do produto, entre em contato com la.cs@teleflex.com ou com seu representante local. Consulte o status da aprovação regulatória local.

BPH Relief. In Sight. UroLift, o logotipo do UroLift, NeoTract, o logotipo da NeoTract, Teleflex, e o logotipo da Teleflex, são marcas comerciais ou marcas comerciais registradas da Teleflex Incorporated ou de suas afiliadas nos EUA e/ou em outros países. ©2021 Teleflex Incorporated. Todos os direitos reservados. Revisado: 11/2021. MC-007135 REV 01 LA EN